The landscape of relapsed or refractory multiple myeloma (RRMM) treatment is shifting toward a more targeted future, as Dr. Sagar Lonial explained. The landscape of relapsed or refractory multiple ...

Researchers and myeloma specialists are developing a new class of drugs called CELMoDs, and they may represent an upgrade to one of the most important treatments patients have relied on for years: ...

Bristol Myers Squibb could be months away from bringing the first 'celmod' to market in the US, after the FDA kicked off a review of the company's iberdomide for relapsed or refractory multiple ...

Editor's note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. We have a lot of new types of therapies in ...

There is a lot of hype on T-cell engagers and CAR T-cell therapy, but there are other new and exciting immunotherapies in myeloma not talked about that may be approved in the near future, according to ...

Scientists at Scripps Research have discovered a critical feature required by a promising new class of cancer drugs, known as CELMoDs, for them to be effective. CELMoDs are designed to attack cancer ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Bristol Myers Squibb has said it hopes to be ready soon to file for approval of its multiple myeloma drug iberdomide after reporting positive results in a phase 3 trial. Full data from the ...

Finding uncovers a key property needed for CELMoD drugs, a type of protein degrader, to work effectively. Scientists at Scripps Research have uncovered a critical feature that a promising new class of ...

Scientists at Scripps Research have uncovered a critical feature that a promising new class of cancer drugs, known as CELMoDs, needs to be effective. CELMoDs are designed to attack cancer in a novel ...

Drs Joshua Richter and Jonathan L. Kaufman consider where IMiDs fall in the RRMM treatment landscape in comparison with emerging treatment options, such as bispecific antibodies and CAR T-cell therapy ...